Figure 4 | Scientific Reports

Figure 4

From: Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care

Figure 4

Estimated first-year-incidences per 100 patients for a first SI by treatment and age. Based on Cox proportional hazards regression as reported in Fig. 3. Inaccurate dates were right imputed. Estimates shown for a seropositive female patient diagnosed since ten years with concomitant conventional synthetic DMARD therapy without glucocorticosteroid use and no history of SIs. SI non-fatal serious infection, TOF tofacitinib, (b)DMARDs (biologic) disease-modifying antirheumatic drugs.

Back to article page